Harri Lahdesmaki
Overview
Explore the profile of Harri Lahdesmaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
116
Citations
4716
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lundgren S, Huuhtanen J, Keranen M, Feng X, Patel B, Ryland G, et al.
Sci Transl Med
. 2025 Feb;
17(787):eadl6758.
PMID: 40009697
Immune aplastic anemia (AA) is a life-threatening bone marrow failure disorder driven by an autoimmune T cell attack against hematopoietic stem and progenitor cells (HSPCs). However, the exact autoantigen targets...
2.
Kurki S, Halla-Aho V, Haussmann M, Lahdesmaki H, Leinonen J, Koskinen M
Sci Rep
. 2024 Jan;
14(1):1731.
PMID: 38243002
A growing body of research is focusing on real-world data (RWD) to supplement or replace randomized controlled trials (RCTs). However, due to the disparities in data generation mechanisms, differences are...
3.
Dufva O, Gandolfi S, Huuhtanen J, Dashevsky O, Duan H, Saeed K, et al.
Immunity
. 2023 Dec;
56(12):2816-2835.e13.
PMID: 38091953
Cancer cells can evade natural killer (NK) cell activity, thereby limiting anti-tumor immunity. To reveal genetic determinants of susceptibility to NK cell activity, we examined interacting NK cells and blood...
4.
Korpela D, Jokinen E, Dumitrescu A, Huuhtanen J, Mustjoki S, Lahdesmaki H
Bioinformatics
. 2023 Dec;
39(12).
PMID: 38070156
Motivation: T cells play an essential role in adaptive immune system to fight pathogens and cancer but may also give rise to autoimmune diseases. The recognition of a peptide-MHC (pMHC)...
5.
Huuhtanen J, Adnan-Awad S, Theodoropoulos J, Forsten S, Warfvinge R, Dufva O, et al.
Leukemia
. 2023 Nov;
38(1):109-125.
PMID: 37919606
Immunological control of residual leukemia cells is thought to occur in patients with chronic myeloid leukemia (CML) that maintain treatment-free remission (TFR) following tyrosine kinase inhibitor (TKI) discontinuation. To study...
6.
Hirvonen M, Lietzen N, Moulder R, Bhosale S, Koskenniemi J, Vaha-Makila M, et al.
Sci Rep
. 2023 Sep;
13(1):15941.
PMID: 37743383
Better understanding of the early events in the development of type 1 diabetes is needed to improve prediction and monitoring of the disease progression during the substantially heterogeneous presymptomatic period...
7.
Dumitrescu A, Jokinen E, Paatero A, Kellosalo J, Paavilainen V, Lahdesmaki H
Bioinformatics
. 2023 Jun;
39(39 Suppl 1):i347-i356.
PMID: 37387131
Motivation: Signal peptides (SPs) are short amino acid segments present at the N-terminus of newly synthesized proteins that facilitate protein translocation into the lumen of the endoplasmic reticulum, after which...
8.
Malonzo M, Lahdesmaki H
BMC Bioinformatics
. 2023 Feb;
24(1):58.
PMID: 36810075
Background: DNA methylation plays an important role in studying the epigenetics of various biological processes including many diseases. Although differential methylation of individual cytosines can be informative, given that methylation...
9.
Huuhtanen J, Kasanen H, Peltola K, Lonnberg T, Glumoff V, Bruck O, et al.
J Clin Invest
. 2023 Jan;
133(6).
PMID: 36719749
BackgroundRelatlimab plus nivolumab (anti-lymphocyte-activation gene 3 plus anti-programmed death 1 [anti-LAG-3+anti-PD-1]) has been approved by the FDA as a first-line therapy for stage III/IV melanoma, but its detailed effect on...
10.
Jokinen E, Dumitrescu A, Huuhtanen J, Gligorijevic V, Mustjoki S, Bonneau R, et al.
Bioinformatics
. 2022 Dec;
39(1).
PMID: 36477794
Motivation: T cells use T cell receptors (TCRs) to recognize small parts of antigens, called epitopes, presented by major histocompatibility complexes. Once an epitope is recognized, an immune response is...